ORCID
- Sumanth Kumbargere Nagraj: 0000-0003-1798-3245
Abstract
Guideline overviewThis guideline is developed as a part of the BE-SAFE project, funded by the European Union's Horizon Europe research and innovation programme and the Swiss State Secretariat for Education, Research and Innovation (SERI)[1]. The overarching goal of BE-SAFE is to improve patient safety by addressing knowledge and practice gaps related to the reduction of Benzodiazepines and Sedative-Hypnotics (BSHs) used for sleep difficulties in Europe. The present recommendations are part of several clinical practice guidelines produced within the second work package of BE-SAFE, specifically on strategies for implementing discontinuation and deprescription of BSHs in patients diagnosed with insomnia disorder.
Publication Date
2023-08-30
Deposit Date
2026-02-25
Funding
This work is part of the project “BE-SAFE: Implementing a patient-centred and evidence-based intervention to reduce BEnzodiazepine and sedative-hypnotic use to improve patient SAFEty and quality of care” supported by the European Union's Horizon Europe research and innovation programme under the grantagreement No 101057123, and by the Swiss State Secretariat for Education, Research and Innovation (SERI) (contract No 22.00116).
Additional Links
Recommended Citation
Nagraj, S. (2023) 'BE-SAFE: Deprescription of benzodiazepine and sedative hypnotics (BSHs) in insomnia disorder: Clinical practice guidelines', Retrieved from https://pearl.plymouth.ac.uk/pds-research/385
